LEI: 213800FLQUB9J289RU66
11 December 2024
BATM
Advanced Communications Limited
("BATM"
or "the Group")
Key milestone achieved with
commencement of NATlab pre-clinical validation
Latest phase begins at major
Italian hospital following successful completion of pre-clinical
trials
BATM (LSE: BVC; TASE: BVC), a leading provider of
real-time technologies for networking solutions and medical
laboratory systems, is pleased to announce that the NATlab
molecular biology platform being developed by ADOR Diagnostics
("ADOR"), an associate company of the Group, has commenced
pre-clinical validation at the Lazzaro Spallanzani National
Institute for Infectious Diseases in Rome, Italy. This marks a key
milestone in the development of NATlab and, the Group believes,
will enable initial sales as well as increase industry awareness
and interest from prospective partners.
The advanced NATlab molecular biology platform
is a point-of-care sample-to-answer solution designed to provide
rapid and accurate diagnosis of infectious disease. It uses a
patented isothermal amplification method for syndromic multiplex
diagnostics to be able to rapidly identify a broad range of
pathogens from a single test.
The commencement of the pre-clinical
validation phase follows the successful completion of pre-clinical
trials, which were conducted at the Tzafom Medical Center in
Israel, to confirm the validity of the biological process that ADOR
has developed and that it can be performed within the NATlab
cartridge and analyser device. NATlab identified all negative
samples and had a 97% sensitivity for the positive samples,
confirming the efficacy of the system and its ability to
out-perform competing solutions available in the market today
because of its multiplex diagnostic capability for rapid and
accurate diagnosis.
ADOR has now made significant progress
with NATlab with the full system entering the pre-clinical
validation phase at the Lazzaro Spallanzani National Institute for
Infectious Diseases in Rome, a leading centre for infectious
disease research and treatment. Successful completion of the
pre-clinical validation is expected to enable initial sales of the
NATlab and the commencement of the regulatory process under the
European Union In Vitro Diagnostic Medical Device Regulation to
become eligible for sale in the EU market.
In addition, following the success of the
pre-clinical trials, ADOR, in collaboration with the Tzafom Medical
Center, has received a grant from the Israel Innovation Authority
to develop a NATlab panel for the diagnosis of stomach ulcers. The
total value is NIS 3.4 million (c. $1 million), which is to be
granted over two years based on the achievement of milestones.
Moti Nagar,
Chief Executive Officer of BATM, said:
"The commencement of the pre-clinical validation
phase at a major European hospital is an important milestone in the
development of NATlab and represents a key stage towards enabling
its market entry. This also follows the successful completion of
pre-clinical trials, which delivered excellent results. As the
value of the substantial IP that has been built within ADOR
continues to increase as well as the industry awareness of the
attractiveness of the NATlab solution, we remain excited about its
prospects and look forward to reporting on further
progress."
Enquiries
|
BATM
|
|
|
Moti Nagar, Chief Executive
Officer
|
+972 9866 2525
|
|
Ran Noy, Chief Financial
Officer
|
|
|
|
|
|
Shore Capital
|
|
|
Mark Percy, Anita Ghanekar, James Thomas
(Corporate Advisory)
|
+44 20 7408 4050
|
|
|
|
|
Gracechurch Group
|
|
|
Harry Chathli, Claire Norbury
|
+44 20 4582 3500
|
Forward-looking
statements
This document contains forward-looking statements. Those
statements reflect the current opinions, evaluations and
estimations of the Group's management, and are based on the current
data regarding the Group's business as is detailed in this document
and in the Group's periodical, interim and immediate reports. The
Group does not undertake any obligation or make any representation
that actual results and events will be in line with those
statements, and stresses that they may differ materially from those
statements, due to changes in the Group's business, market,
competition, demand for the Group's products or services, general
economic factors or other factors that can influence the Group's
business and results, due to the risk factors that are detailed in
the Group's Annual Report, and due to information and factors that
are currently unknown to the Group's management and that, if known,
would affect the management's opinions, evaluations or estimations.
The Group will report the actual results and events according to
its legal, accounting and regulatory obligations, and does not
undertake any other obligation to report them or their deviations
from the forward-looking statements, or to update any of the
forward-looking statements in this document or to report that it is
not valid anymore.
